Disitamab vedotin, an antibody-drug conjugate (ADC), targets HER2-expressing cancer cells. It works by binding to HER2, being ...

The findings suggest that enfortumab vedotin, especially combined with pembrolizumab, offers promising beneficial outcomes in metastatic urothelial carcinoma treatment,” researchers wrote.

Updated data "reinforce enfortumab vedotin and pembrolizumab as the new standard of care in frontline urothelial cancer,” said Thomas Powles, MD, MBBS.

In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.

The addition of brentuximab vedotin to lenalidomide and rituximab improved survival for certain patients with DLBCL. A similar percentage of patients in each arm experienced treatment-emergent ...

Starting in mid-2025, the Big Pharma will kick off trials of Summit’s bispecific and its vedotin ADCs in individual, distinct solid tumor types. Vedotin is the payload in a clutch of ADCs that ...

The US company is paying $200 million upfront for rex-Asian rights to RemeGen's disitamab vedotin, with another $2.4 billion in possible future payments tied to future successes across multiple ...

BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China ...

Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252] Technology appraisal guidance Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant ...